Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

289
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
289
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

415
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
415
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

350
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
350
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

237
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
237
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

597
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
597
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

370
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
370

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of centre experience on complete clinical and haemodynamic response after alcohol septal ablation for hypertrophic obstructive cardiomyopathy.

International journal of cardiology·2025
Same author

Hypertrophic Cardiomyopathy With Midventricular Obstruction Is Not Nonobstructive Hypertrophic Cardiomyopathy.

JACC. Heart failure·2025
Same author

Does the surgical access matter in myectomy for hypertrophic obstructive cardiomyopathy?

International journal of cardiology·2025
Same author

Alcohol septal ablation in hypertrophic obstructive cardiomyopathy: The more the better?

International journal of cardiology·2025
Same author

Retrofitting the Heart: Explaining the Enigmatic Septal Thickening in Hypertrophic Cardiomyopathy.

Circulation. Heart failure·2024
Same author

Low-grade systemic inflammation and left ventricular dysfunction in hypertensive compared to non-hypertensive hypertrophic cardiomyopathy.

International journal of cardiology·2023
Same journal

[Advancing cardiovascular prevention : Evidence-based design of healthy and sustainable food environments].

Herz·2026
Same journal

[Effects of air pollution on cardiovascular health].

Herz·2026
Same journal

[Heart and climate].

Herz·2026
Same journal

Multidimensional psychosocial screening in routine cardiac care: preliminary findings from a cross-sectional survey.

Herz·2026
Same journal

[Noise and the heart].

Herz·2026
Same journal

[The cardiovascular exposome: areas of action for prevention and practical cardiology].

Herz·2026
See all related articles

Related Experiment Video

Updated: Dec 26, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.1K

[Hypertrophic cardiomyopathy].

Angelika Batzner1, Hubert Seggewiß2

  • 1Deutsches Zentrum für Herzinsuffizienz, Am Schwarzenberg 15, Haus 15A, Würzburg, 97078, Deutschland.

Herz
|March 19, 2020
PubMed
Summary
This summary is machine-generated.

Hypertrophic cardiomyopathy, a common genetic heart disease, often causes left ventricular outflow tract obstruction. Treatment involves managing symptoms, preventing sudden cardiac death with devices like ICDs, and considering septal ablation or myectomy when medications fail.

Keywords:
MyectomyMyocardial thickeningObstructionSeptal ablationSudden cardiac death

More Related Videos

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

6.1K
Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

17.7K

Related Experiment Videos

Last Updated: Dec 26, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.1K
An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

6.1K
Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

17.7K

Area of Science:

  • Cardiology
  • Genetics
  • Internal Medicine

Background:

  • Hypertrophic cardiomyopathy (HCM) is the most prevalent inherited cardiac condition, affecting 0.2-0.6% of the population.
  • A key feature in 70% of patients is dynamic obstruction of the left ventricular outflow tract.
  • Symptoms vary widely and are linked to preload/afterload changes, with a significant risk of sudden cardiac death, especially in younger individuals.

Purpose of the Study:

  • To outline diagnostic and prognostic considerations for hypertrophic cardiomyopathy.
  • To discuss therapeutic strategies for symptomatic relief and sudden cardiac death prevention.
  • To review interventional treatment options when medical management is insufficient.

Main Methods:

  • Review of diagnostic measures for hypertrophic cardiomyopathy.
  • Evaluation of prognostic factors and risk stratification for sudden cardiac death.
  • Assessment of medical, interventional (septal ablation), and surgical (myectomy) treatment approaches.

Main Results:

  • Variable clinical presentation influenced by hemodynamic factors.
  • Identification of patients at high risk for sudden cardiac death warranting implantable cardioverter-defibrillator (ICD) implantation.
  • Septal ablation and surgical myectomy are effective first-line treatments when medication fails, chosen based on patient morphology and surgical expertise.

Conclusions:

  • Effective management of hypertrophic cardiomyopathy requires a multi-faceted approach.
  • Risk stratification and timely intervention, including ICDs, are crucial for preventing sudden cardiac death.
  • Interventional and surgical options provide valuable alternatives for patients with refractory symptoms.